Sandoz UK promotes Tim de Gavre to country head

Novartis’ generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK.

De Gavre has served at Sandoz for seven years to date, initially joining as its global head of strategy for the biosimilars business unit based in Germany.

Prior that that he worked at McKinsey & Company and brings almost 20 years of healthcare, consulting and marketing experience to the firm.

He said: “I am immensely proud to be asked to lead the Sandoz UK team.

“As a market, the UK has one of the highest levels of generic use of any global market, and the NHS is also under severe cost pressures.

“Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS manage these cost-pressures.”

“As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”

De Gavre succeeds Stephan Eder, who will take over the role of country head for Sandoz Germany.

In that role Eder will be responsible for all commercial and medical activities for Sandoz, Hexal and 1A pharma in Germany.